These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 30135644)
1. Repositioning Microtubule Stabilizing Drugs for Brain Disorders. Varidaki A; Hong Y; Coffey ET Front Cell Neurosci; 2018; 12():226. PubMed ID: 30135644 [TBL] [Abstract][Full Text] [Related]
2. Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB ACS Chem Neurosci; 2017 Jan; 8(1):5-7. PubMed ID: 28095679 [TBL] [Abstract][Full Text] [Related]
3. Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules. Miller JH; Das V Curr Pharm Des; 2020; 26(35):4362-4372. PubMed ID: 32564745 [TBL] [Abstract][Full Text] [Related]
4. Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. Brunden KR; Lee VM; Smith AB; Trojanowski JQ; Ballatore C Neurobiol Dis; 2017 Sep; 105():328-335. PubMed ID: 28012891 [TBL] [Abstract][Full Text] [Related]
5. The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders. Eira J; Silva CS; Sousa MM; Liz MA Prog Neurobiol; 2016 Jun; 141():61-82. PubMed ID: 27095262 [TBL] [Abstract][Full Text] [Related]
6. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Benitez-King G; Ramírez-Rodríguez G; Ortíz L; Meza I Curr Drug Targets CNS Neurol Disord; 2004 Dec; 3(6):515-33. PubMed ID: 15581421 [TBL] [Abstract][Full Text] [Related]
7. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Magen I; Gozes I Neuropeptides; 2013 Dec; 47(6):489-95. PubMed ID: 24210139 [TBL] [Abstract][Full Text] [Related]
8. A New Quantitative Cell-Based Assay Reveals Unexpected Microtubule Stabilizing Activity of Certain Kinase Inhibitors, Clinically Approved or in the Process of Approval. Ramirez-Rios S; Michallet S; Peris L; Barette C; Rabat C; Feng Y; Fauvarque MO; Andrieux A; Sadoul K; Lafanechère L Front Pharmacol; 2020; 11():543. PubMed ID: 32425788 [TBL] [Abstract][Full Text] [Related]
9. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Field JJ; Kanakkanthara A; Miller JH Bioorg Med Chem; 2014 Sep; 22(18):5050-9. PubMed ID: 24650703 [TBL] [Abstract][Full Text] [Related]
10. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents. Tangutur AD; Kumar D; Krishna KV; Kantevari S Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738 [TBL] [Abstract][Full Text] [Related]
11. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Fanale D; Bronte G; Passiglia F; Calò V; Castiglia M; Di Piazza F; Barraco N; Cangemi A; Catarella MT; Insalaco L; Listì A; Maragliano R; Massihnia D; Perez A; Toia F; Cicero G; Bazan V Anal Cell Pathol (Amst); 2015; 2015():690916. PubMed ID: 26484003 [TBL] [Abstract][Full Text] [Related]
13. Microtubule dynamics and the neurodegenerative triad of Alzheimer's disease: The hidden connection. Brandt R; Bakota L J Neurochem; 2017 Nov; 143(4):409-417. PubMed ID: 28267200 [TBL] [Abstract][Full Text] [Related]
14. Targeting microtubules for cancer chemotherapy. Zhou J; Giannakakou P Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262 [TBL] [Abstract][Full Text] [Related]
15. Microtubule and microtubule associated protein anomalies in psychiatric disease. Marchisella F; Coffey ET; Hollos P Cytoskeleton (Hoboken); 2016 Oct; 73(10):596-611. PubMed ID: 27112918 [TBL] [Abstract][Full Text] [Related]
16. Neurodegeneration and microtubule dynamics: death by a thousand cuts. Dubey J; Ratnakaran N; Koushika SP Front Cell Neurosci; 2015; 9():343. PubMed ID: 26441521 [TBL] [Abstract][Full Text] [Related]
17. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies. Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057 [TBL] [Abstract][Full Text] [Related]
18. The direct and indirect effects of α-synuclein on microtubule stability in the pathogenesis of Parkinson's disease. Carnwath T; Mohammed R; Tsiang D Neuropsychiatr Dis Treat; 2018; 14():1685-1695. PubMed ID: 29983568 [TBL] [Abstract][Full Text] [Related]
19. Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders. Bonini SA; Mastinu A; Ferrari-Toninelli G; Memo M Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933765 [TBL] [Abstract][Full Text] [Related]
20. Amyloid peptide toxicity and microtubule-stabilizing drugs. Michaelis ML; Chen Y; Hill S; Reiff E; Georg G; Rice A; Audus K J Mol Neurosci; 2002; 19(1-2):101-5. PubMed ID: 12212764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]